Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic
2010
Abstract
We report here the first experiences with dasatinib therapy in 71 CML patients resistant or intolerant to imatinib from the real clinical practice of 6 hematological centers in the Czech Republic. Our clinical experiences, described here, confirmed that dasatinib is associated with high response rates especially in imatinib resistant or intolerant CML patients in chronic phase.
In chronic phase (n=46), complete hematological reponse (CHR) was achieved in 97%, complete cytogenetic response (CCgR) in 67%. 10.4149/neo_2010_04_355